CARsgen Therapeutics appoints Senior Vice President of Global Regulatory Affairs

CARsgen Therapeutics has appointed Dr. Sylvie Peltier as Senior Vice President of Global Regulatory Affairs, effective October 31.

CARsgen focuses on CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, with operations in China and the US.

Dr. Peltier will be responsible for developing global regulatory strategies, leading and driving the company’s regulatory affairs activities, and initiatives in support of IND/CTA/BLA filing and approval of developmental products globally.

She has extensive global leadership and hands-on experiences in clinical and CMC regulatory affairs across several multinational pharmaceutical and biopharmaceutical companies. Prior to joining CARsgen, she served as Vice President, Head of US Regulatory Affairs at MorphoSys US since 2020, and as Head of Regulatory Affairs at Servier Pharmaceuticals from 2018.

Before joining Servier Pharmaceuticals LLC, Dr. Peltier served at Cephalon since 2007, an international biopharmaceutical company which was acquired later by TEVA Pharmaceuticals Industries, holding various positions from Senior Director, Europe Regulatory Affairs, CNS/Pain and CMC, Senior Director, US Regulatory Affairs, to Senior Director, Clinical Search Evaluation and Due Diligence. Previously, she worked at Pfizer Regulatory Affairs from 1995.

Dr. Peltier earned a Diploma of Pharmacy Doctorate and a Diploma of Graduated Specialized Studies (DESS) in Health Law from University of Paris XI in Paris, France.